Liver cancer is one of the leading causes of cancer death, with new cases predicted to rise by an alarming 70% by the time we reach 2025 (vs. 2022). Hepatocellular carcinoma, or HCC, accounts for 90% of cases, and poses significant challenges in treatment. Access this in-depth report to explore the global drug development landscape, and how promising advances in treatments are providing hope for the future. Explore topics including:

• Evolution of treatments - from traditional chemotherapy to targeted therapies, immunotherapy and transarterial therapies
• Global clinical trial landscape, including stats on patient recruitment, trial density and growth trends by region
• Role of public and venture capital funding
• Future innovations and collaboration boosting survival rates
• SWOT analysis on LC management